Revolution- Study drug RMC-5127 for advanced KRAS G12V solid tumors (RMC-5127-001) - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
[RMC-5127-001] Phase 1/1b, Multicenter, Open-Label, Study of RMC-5127 in Patients with Advanced KRAS G12V-Mutant Solid Tumors
Principal Investigator
John H. Strickler, MD
Medical Oncologist
Protocol Number
IRB:
PRO00119569
NCT:
NCT07349537
Phase
Phase I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu